Cyp4f13 inhibitors are a chemical class that specifically target the activity of the Cyp4f13 enzyme, a member of the cytochrome P450 superfamily. This family of enzymes is known for its role in catalyzing the oxidation of organic substances, particularly in the metabolism of fatty acids, steroids, and xenobiotics. Cyp4f13, like other P450 enzymes, is involved in the metabolism of various endogenous and exogenous compounds through oxidative reactions. Its specific substrate profile may include fatty acid derivatives and bioactive lipids, which play crucial roles in cellular processes such as signaling, membrane dynamics, and energy homeostasis. By inhibiting Cyp4f13, these chemicals can modulate the enzyme's ability to process its substrates, leading to changes in the concentration and activity of metabolites within the cell.
The use of Cyp4f13 inhibitors allows researchers to explore the enzyme's specific functions in metabolic pathways, especially those involving lipid metabolism. These inhibitors serve as important tools for dissecting the role of Cyp4f13 in maintaining the balance of lipid-derived molecules and in regulating metabolic networks. Inhibition of Cyp4f13 can affect various downstream processes, such as lipid signaling, oxidative stress response, and detoxification pathways. Studying these inhibitors provides insights into the enzyme's contribution to homeostasis and its interactions with other metabolic pathways. Furthermore, Cyp4f13 inhibitors are valuable for understanding the regulatory mechanisms that control the enzyme's expression and activity, offering a deeper understanding of how the cytochrome P450 family functions in broader biochemical contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin may downregulate Cyp4f13 by binding to and activating pregnane X receptor (PXR), which can suppress the expression of certain P450 enzymes, including Cyp4f13. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone might reduce Cyp4f13 levels by activating glucocorticoid receptors that can initiate a transcriptional cascade suppressing the expression of this enzyme. | ||||||
Lead(II) Acetate | 301-04-2 | sc-507473 | 5 g | $85.00 | ||
Lead acetate may induce oxidative stress and subsequent signaling pathways that result in the reduced expression of hepatic enzymes, including Cyp4f13. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Clofibrate could decrease Cyp4f13 expression by activating peroxisome proliferator-activated receptors (PPARs) that alter lipid metabolism and may suppress some P450 enzymes. | ||||||
Isoniazid | 54-85-3 | sc-205722 sc-205722A sc-205722B | 5 g 50 g 100 g | $26.00 $101.00 $146.00 | ||
Isoniazid could diminish Cyp4f13 expression by covalent modification of the heme group in P450 enzymes, which could affect the stability and expression of the enzyme. | ||||||
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $90.00 $146.00 $469.00 $791.00 | 18 | |
Cyclophosphamide may reduce Cyp4f13 expression through its metabolites, which could interfere with the transcriptional machinery responsible for the expression of this enzyme. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Omeprazole could inhibit Cyp4f13 expression by irreversibly binding to the enzyme′s heme group, which may lead to a compensatory decrease in expression levels. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine, by inhibiting serotonin reuptake, could disrupt cellular signaling pathways that might result in the downregulation of Cyp4f13 expression in the liver. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
Gemfibrozil might lower Cyp4f13 expression by activating liver PPARs, which could shift the expression profile of cytochrome P450 enzymes, resulting in decreased Cyp4f13 levels. | ||||||